Trial record 1 of 1 for:
duthy
Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial (DUTHY)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03753919 |
|
Recruitment Status :
Active, not recruiting
First Posted : November 27, 2018
Last Update Posted : November 13, 2023
|
Sponsor:
Grupo Espanol de Tumores Neuroendocrinos
Collaborator:
MFAR
Information provided by (Responsible Party):
Grupo Espanol de Tumores Neuroendocrinos
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Estimated Primary Completion Date : | July 2024 |
| Estimated Study Completion Date : | December 2024 |